← All trials
NCT05070468
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 22, 2020
- Primary completion
- Jan 21, 2021
- Completion date
- Mar 21, 2021
- First posted
- Oct 7, 2021
- Last posted
- Oct 7, 2021
- Enrollment
- 84
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Alborz Medical UniversityLead sponsor
- Alborz Medical UniversityStudy director
- Alborz Medical UniversityReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.